Kristin Bundy

https://www.kristinbundy.com/

Truth be told, Kristin always wanted to be a doctor. It took her 2 years of pre-med training to realize that she scored better on essay exams than multiple-choice tests, which were the bane of her existence in undergrad science classes! So she turned to medical writing, and for 20+ years, she's worked in scientific journalism, CME/CE, and pharmaceutical advertising. She has also made a few stops along the way to get her advanced certificate in wine and spirits from the London-based Wine & Spirit Education Trust and earn 3 yoga-teacher certifications.

All articles by Kristin Bundy

ASCO 2019

RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC

Kristin Bundy

June 14, 2019

RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.

Several preclinical studies provided more refined and nuanced insights into the target itself, and bioinformatics uncovered a way to measure low levels of residual disease during morphologic remission.

Hematologic Cancers

Update from AACR: Divergent Data on FLT3 Inhibitors Tell a Tale of 2 Outcomes in AML and mCRC

Kristin Bundy

May 28, 2019

Several preclinical studies provided more refined and nuanced insights into the target itself, and bioinformatics uncovered a way to measure low levels of residual disease during morphologic remission.

Data from a phase 2 trial of nivolumab + ipilimumab in NSCLC suggest that tumor mutational burden may be a superior biomarker to PD-L1 expression.

Lung Cancer

Dual Immunotherapy and an Emerging Biomarker in NSCLC

Kristin Bundy

April 3, 2019

Data from a phase 2 trial of nivolumab + ipilimumab in NSCLC suggest that tumor mutational burden may be a superior biomarker to PD-L1 expression.

Next post in Lung Cancer

Kristin Bundy

All articles by Kristin Bundy

RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC

Update from AACR: Divergent Data on FLT3 Inhibitors Tell a Tale of 2 Outcomes in AML and mCRC

Dual Immunotherapy and an Emerging Biomarker in NSCLC

Perioperative Beta-Blocker in Lung Cancer: Intriguing Suggestion of Survival Benefit